(LabManager) New survey results from the Pistoia Alliance, the Quantum Economic Development Consortium (QED-C) and QuPharm show almost one-third (31 percent) of life science organizations polled are set to begin quantum computing evaluation this year. A further 39 percent are planning to evaluate next year or have quantum computing ‘on their radar,’ while 30 percent have no current plans to evaluate.
The three organizations have collaborated to establish a cross-industry Community of Interest (CoI) to explore the opportunities for quantum computing to enhance the efficiency and effectiveness of biopharma R&D. The CoI aims to support companies that need help navigating the pathway to quantum computing and will facilitate collaboration between stakeholders, propose new ideas for quantum computing projects, and help interested parties define and articulate potential use cases.
“The interest in quantum computing across many sectors is high, yet most biopharmaceutical companies are only just beginning the journey and exploring the potential for accelerating discovery,” commented Emir Roach, one of the leaders of QuPharm. “Quantum computing is a completely new paradigm of computing, and our mission is to accelerate its implementation in life sciences. We are looking forward to working with the Pistoia Alliance and QED-C to help educate the life science and health care industry on the benefits.”